Table 2.
Methylation status of CDH1, CDKN2A, DAPK and TIMP2 genes
| Patient no/sample | Methylation | |||
|---|---|---|---|---|
| CDH1 | CDKN2A | DAPK | TIMP2 | |
| 4 T | M | M | M | M |
| 4 PM | M | M | M | M |
| 4 DM | U | M | M | M |
| 7 T | U | U | U | M |
| 7 PM | M | U | M | M |
| 7 DM | M | U | M | M |
| 8 T | U | U | M | M |
| 8 DM | U | U | M | M |
| 1 T | NA | M | M | NA |
| 1 DM | U | U | M | NA |
| 9 T | U | U | M | M |
| 9 DM | NA | U | M | M |
| Methylation tumor (%) | 1/5 (20 %) | 2/5 (40 %) | 4/5 (80 %) | 4/5 (80 %) |
| Methylation adjacent margin (%) | 3/7 (43 %) | 2/7 (28 %) | 7/7 (100 %) | 6/7 (86 %) |
NA not amplified, U unmethylated, M methylated, T tumor, PM proximal margin (2 cm), DM distal margin (5 cm)